Company Focus
Eli Lilly & Company
Latest Eli Lilly & Company News
Pharmaceutical
A new broader label for heart med Jardiance (empagliflozin) will help developers Eli Lilly and Boehringer Ingelheim extend the increasingly lucrative franchise. 25 February 2022
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Eli Lilly & Company
Biotechnology
Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. 25 September 2024
Pharmaceutical
Japanese drugmaker Eisai closed down 2.3% at 5,587 yen today, despite news of regulatory approvals for two of its drugs. 24 September 2024
Biotechnology
Japan’s Daiichi Sankyo and Anglo-Swedish pharma major AstraZeneca were trading lower on Tuesday after announcing topline results from the TROPION-Breast01 study. 24 September 2024
Biotechnology
In a news packed morning, Japanese drugmaker Astellas Pharma today revealed two regulatory approvals. 24 September 2024
Biotechnology
Takeda has announced the Japanese approval of Fruzaqla (fruquintinib) capsules 1mg/5mg, a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, to treat advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chemotherapy. 24 September 2024
Pharmaceutical
Japan’s Ministry of Health, Labor and Welfare of Japan (MHLW) has approved New Drug Application (NDA) for Quviviq (daridorexant; ACT-541468) 25mg and 50mg for the treatment of adult patients with insomnia, submitted by Nxera Pharma. 24 September 2024
Pharmaceutical
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
Pharmaceutical
Israeli drugmaker Teva Pharmaceuticals has announced new findings from research that could shape treatment strategies in schizophrenia and tardive dyskinesia (TD). 23 September 2024
Biotechnology
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Hetronifly (serplulimab). 23 September 2024
Latest In Brief for Eli Lilly & Company
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest Related Ones To Watch News
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
13 November 2024
12 November 2024
5 November 2024
5 November 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze